




RealRate

PHARMACEUTICAL 2026

ANI Pharmaceuticals INC
Rank 86 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of ANI Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ANI Pharmaceuticals INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 64% points. The greatest weakness of ANI Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 6.6% points above the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	753,117
Cost of Goods Sold	0
Intangible Assets	542,006
Liabilities, Current	278,112
Liabilities, Non-Current	304,004
Other Assets	82,778
Other Compr. Net Income	-4,311
Other Expenses	420,318
Other Liabilities	317,537
Other Net Income	-15,302
Other Revenues	883,366
Property and Equipment	62,476
Research and Development	51,664
Selling, General and Administrative Expense	317,745

Output Variable	Value in 1000 USD
Assets	1,440,377
Liabilities	899,653
Expenses	789,727
Revenues	883,366
Stockholders Equity	540,724
Net Income	78,337
Comprehensive Net Income	76,182
BaseVar	2,016,368
ECR before Limited Liability	107%
Economic Capital Ratio	236%